Navigation Links
Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Date:9/30/2010

WALTHAM, Mass., Sept. 30 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) reported today that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.  This study is a double-blind, placebo-controlled trial designed to assess the efficacy of 8 weeks of treatment with RG2417 or a placebo on the symptoms of bipolar depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS).  The study enrolled 175 patients at 29 clinical sites within the United States, and we expect to report top-line results in the first quarter of 2011.

The primary objective of this study is to assess the safety and efficacy of RG2417 on the symptoms of bipolar depression by demonstrating a greater improvement in the MADRS score of the patients receiving RG2417 when compared to placebo over the 8-week treatment period.  Patients were initially screened for a score of bipolar depression symptoms of greater than 20 on the MADRS and subsequently confirmed to meet the criteria for bipolar depression using an alternate diagnostic tool to ensure that patients have the appropriate diagnosis for inclusion in the study.  Evaluations for symptoms of depression are conducted at baseline and then weekly using the MADRS, a standardized, rater-administered scale, which has been used for numerous drug trials in bipolar disorder.  In addition to the MADRS ratings, patients conduct a weekly self-assessment of their symptoms, which is used to cross check the fidelity of the MADRS raters.  Additional secondary and exploratory objectives include improvements in the Clinical Global Impression Scale, difference in the end of study MADRS scores, and a lack of increase in mania as measured by the Young's Mania Rating Scale.

The average baseline MADRS of the 175 patients
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
2. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
3. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
4. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
5. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
6. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
7. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
8. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
9. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
10. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
11. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... 16, 2013  Alere Inc. (NYSE: ALR ), ... their health at home through the merger of rapid diagnostics ... per share on its Series B Convertible Perpetual Preferred Stock ... to holders of record of Series B stock at the ... payment will cover the amount of all dividends accrued from ...
(Date:5/16/2013)... 2013 OrthoView PSL will allow ... access the widely-used OrthoView digital templating software via the ... to get started. OrthoView, the leading independent ... years, is dedicated to enabling orthopaedic surgeons in hospitals ... when printed film is unavailable. Over 5,000 orthopaedic surgeons ...
(Date:5/16/2013)... , May 16, 2013  A new survey ... living with vulvar and vaginal atrophy (VVA) are either ... or are simply dissatisfied with the therapies available. The ... ,s VI ews of Treatment Options for Menopausal ... to the treatment of VVA, including lack of knowledge, ...
Breaking Medicine Technology:OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy 2New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy 3
... The National Association of Drug Diversion Investigators ... between law enforcement, healthcare professionals, state regulatory agencies ... of drug diversion – today released the following ... Substance Abuse and Mental Health Services Administration (SAMHSA) ...
... Sept. 12, 2011 A revolutionary new imaging device ... - - the VivoSight® Optical Coherence Tomography ... in the U.S. for the first time.  The VivoSight® ... instantly, providing additional information which will allow them to ...
Cached Medicine Technology:Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 2Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 3Revolutionary Device for Use in Detecting Non-Melanoma Skin Cancer in Real Time, Alleviates Patient Stress, Can Reduce Invasive Biopsy 4
(Date:5/18/2013)... (PRWEB) May 18, 2013 The product liability ... lawsuits on behalf of consumers nationwide who have sustained ... Shape-Ups toning shoes. These cases are all part of MDL ... Skechers lawsuits will be heard in the U.S. ... , Wright & Schulte, LLC specializes in defending the ...
(Date:5/17/2013)... Allen J. Schultz, D.D.S., is making the Laser ... available to residents of San Juan Capistrano. The laser ... than relying on a scalpel to cut the tissue away. ... on tightly defined wavelengths to target the diseased tissue and ... Only about one in every hundred dental professionals is trained ...
(Date:5/17/2013)... 2013 Stryker hip lawsuit claims ... and ABG II Modular-Neck Hip Stem recall continue to move ... According to court documents, a Case Management Conference was ... at which time the Court, among other things, set deadlines ... must submit Fact Sheets to Defendant and Liaison Counsel. ...
(Date:5/17/2013)... N.C., (PRWEB) May 17, 2013 Charlotte’s ... share the spotlight with children served by the Muscular ... event on Tuesday, May 21 at Bank of ... Team is a unique social event that pairs top ... fire fighters, with an “MDA Buddy” (a local child ...
(Date:5/17/2013)... 17, 2013 Parker Waichman LLP ... rights of victims injured by defective medical devices, notes ... said in a May 16, 2013, statement ... and ceramic-on-metal hip replacement products; specifically, the metal liners ... Acetabular Hip System will no longer be available worldwide ...
Breaking Medicine News(10 mins):Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 2Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 3Health News:Ten Skechers Lawsuits Filed by Wright & Schulte on Behalf of Consumers Who Sustained Severe Tendon Damage Allegedly Due to Wearing Skechers Shape-Ups 4Health News:San Clemente, CA Periodontist, Dr. Allen J. Schultz, Now Provides Laser Gum Disease Treatment to Southern Orange County Periodontal Disease Patients 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 2Health News:Stryker Hip Lawsuit News: Bernstein Liebhard LLP Reports on Recent Case Management Conference in New Jersey Stryker Hip Recall Litigation 3Health News:MDA Hosts Annual Charlotte Muscle Team Event 2Health News:MDA Hosts Annual Charlotte Muscle Team Event 3Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 2Health News:Parker Waichman LLP Responds to Johnson & Johnson’s Decision to Discontinue Some of Its DePuy All-metal and Ceramic-on-metal Hip Implant Products 3
... now widespread, CDC survey finds , MONDAY, April 26 ... have either high blood pressure, high cholesterol or diabetes, ... and other cardiovascular problems, a new government survey finds. ... and Nutrition Examination Survey (NHANES) 1999-2006 shows that 45 ...
... applauds President Obama,s selection of Donald Berwick, M.D., to ... and Medicaid Services. ASTRO looks forward to working closely ... critical healthcare reforms for patients and work toward system ... quality of care patients receive. ASTRO,s highest priority is ...
... Patients can decrease the frequency of Botox Cosmetic injections ... the same wrinkle-smoothing cosmetic benefits, according to new research ... two years of treatment at recommended intervals, patients can ... their Botox treatments by half," said Roger A. Dailey, ...
... type of immune cell are higher in head and neck cancer ... according to researchers at the University of Michigan Comprehensive Cancer Center. ... are most likely to respond to chemotherapy and radiation and allow ... the past, we would give toxic chemotherapy to a patient, look ...
... still time for media to register for the largest ... and publish early results from the International Polar Year ... Conference, WHEN: June 8 to 12, 2010, WHERE: Norway ... Oslo), MEDIA REGISTRATION: http://www.ipy-osc.no/article/2010/1265207747.88 The conference ...
... , ... Finn,s first book on both sides of the Atlantic. This layman,s account of his interest ... their own self worth, regardless of historical, cultural or religious backgrounds, as it strives to ... ...
Cached Medicine News:Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 2Health News:Nearly Half of U.S. Adults Have Heart Risk Factors 3Health News:Botox reduces wrinkles even in less frequent doses 2Health News:Immune cells predict success of head and neck cancer treatment, U-M study finds 2Health News:World's largest polar science conference to take place in Oslo 2Health News:World's largest polar science conference to take place in Oslo 3Health News:Life Coach and Author Thomas Finn's Highly Anticipated Book, 'A Better Tomorrow- Affirmations and Visualizations the Keys to Success,' Debuts June 15 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: